Skip to main content
Erschienen in: Drug Safety 6/2002

01.05.2002 | Short Communication

Effects of Coding Dictionary on Signal Generation

A Consideration of Use of MedDRA Compared with WHO-ART

verfasst von: Dr Elliot G. Brown

Erschienen in: Drug Safety | Ausgabe 6/2002

Einloggen, um Zugang zu erhalten

Abstract

To support signal generation a terminology should facilitate recognition of medical conditions by using terms which represent unique concepts, providing appropriate, homogeneous grouping of related terms. It should allow intuitive or mathematical identification of adverse events reaching a threshold frequency or with disproportionate incidence, permit identification of important events which are commonly drug-related, and support recognition of new syndromes.
It is probable that the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms (PTs) or high level terms (HLTs) will be used to represent adverse events for the purposes of signal generation. A comparison with 315 WHO Adverse Reaction Terminology (WHO-ART) PTs showed that for about 72% of WHO-ART PTs, there were one or two corresponding MedDRA PTs. However, there were instances where there were many MedDRA PTs corresponding to single WHO-ART PTs. In many cases, MedDRA HLTs grouped large numbers of PTs and sometimes there could be problems when a single HLT comprises PTs which represent very different medical concepts, or conditions which differ greatly in their clinical importance.
Further studies are needed to compare the way in which identical data sets coded with MedDRA and with other terminologies actually function in generating and exploring signals using the same methods of detection and evaluation.
Fußnoten
1
MedDRA is a registered trademark of the International Federation of Pharmaceutical Manufacturers Associations.
 
Literatur
1.
Zurück zum Zitat Brown EG, Wood KL, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 202): 109–17PubMedCrossRef Brown EG, Wood KL, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 202): 109–17PubMedCrossRef
2.
Zurück zum Zitat Brown EG, Douglas S. Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities. Pharmacoepidemiol Drug Saf 2000; 9: 479–91CrossRef Brown EG, Douglas S. Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities. Pharmacoepidemiol Drug Saf 2000; 9: 479–91CrossRef
3.
Zurück zum Zitat Benefit-risk balance for marketed drugs: evaluating safety signals. Report of CIOMS Working Group IV. Geneva: CIOMS, 1998 Benefit-risk balance for marketed drugs: evaluating safety signals. Report of CIOMS Working Group IV. Geneva: CIOMS, 1998
4.
Zurück zum Zitat Edward R, Lindquist M, Wiholm BE. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156–8CrossRef Edward R, Lindquist M, Wiholm BE. Quality criteria for early signals of possible adverse drug reactions. Lancet 1990; 336: 156–8CrossRef
5.
Zurück zum Zitat Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483–6PubMedCrossRef Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483–6PubMedCrossRef
6.
Zurück zum Zitat European Commission. The rules governing medicinal products in the European union. Vol 9. Pharmacovigilance, medicinal products for human and veterinary use. European Commission [online]. Available from URL: http://www.eudraportal.eudra.org [Accessed 2001 Dec] European Commission. The rules governing medicinal products in the European union. Vol 9. Pharmacovigilance, medicinal products for human and veterinary use. European Commission [online]. Available from URL: http://​www.​eudraportal.​eudra.​org [Accessed 2001 Dec]
Metadaten
Titel
Effects of Coding Dictionary on Signal Generation
A Consideration of Use of MedDRA Compared with WHO-ART
verfasst von
Dr Elliot G. Brown
Publikationsdatum
01.05.2002
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 6/2002
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.2165/00002018-200225060-00009

Weitere Artikel der Ausgabe 6/2002

Drug Safety 6/2002 Zur Ausgabe